Tag: B-cell
A New Method to Generate Human Antibodies
Traditionally, the production of antibodies, considered the molecular workhorses of protein research, has been slow and complex. Less than a decade ago, generating research-grade...
SAR3419 Achieved Objective Responses Well Above Study Threshold and was Found...
A novel anticancer therapeutic called coltuximab ravtansine (CoR; SAR3419; Sanofi) shows favorable results in the Phase II STARLYTE trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a humanized CD19 mAb linked to DM4, a maytansine analog, developed by ImmunoGen.
Results from Phase I Trial with SGN-CD19A Shows Encouraging Anti-tumor Activity...
esults from an interim phase I clinical trial presented at the 50th Annual Meeting of the American Association of Clinical Oncology (ASCO), being held May 30 - June 3, 2014 in Chicago, Ill, shows that SGN-CD19A (Seattle Genetics, Inc, Bothell, WA 98021, USA), an antibody-drug conjugate or ADC in development for the treatment of B-cell malignancies, offers encouraging anti-tumore activity in patients with Non-Hodgkin Lymphoma (NHL).[1]
Ongoing Phase I Clinical Trial of SGN-CD19A Demonstrates Encouraging Activity and...
Phase I interim data from a clinical trial with SGN-CD19A being developed for the treatment of B-cell malignancies, including acute lymphoblastic leukemia or ALL -- shows...
